EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

EarliPoint Marketing Toolkit

Partner Tools and Resources

This page includes ready-to-use EarliPoint materials for partners to download and share. Use these resources to explain what EarliPoint is, support conversations with providers and families, and keep messaging aligned across every touchpoint.

Indication Statement: The EarliPoint Assessment device is indicated as a tool to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children ages 16 months through 95 months (7 years), who are at risk based on concerns identified by a parent, caregiver, or healthcare provider.

Download the EarliPoint Style Guide

Download

Download the EarliPoint Logo Pack

Download

Marketing Materials

Download the EarliPoint Overview for Pediatric Providers

Download

Download the EarliPoint Guide for Parents

Download

EarliPoint Health Video

Download

Download the EarliPoint Guide for Parents (Customizable Version)

Download

Download the EarliPoint Guide for Parents (Customizable Canva Version)

View & Make a Copy on Canva
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder